Frontiers in Clinical Drug Research: Anti-Infectives

Atta-ur-Rahman, _; Ali, A. N.; Haque, Ahsanul; Dupont, Aline; Rattan, Ashok; Haque, Asma; Gürel, Aynur; Schittl, Beate; Huang, David B.; Altındiş, Emrah; Krause, E; Tejada, Guillermo Martínez de; Koo, Hoonmo L.; Bai, Hui; Gürhan, İsmet Deliloğlu; Hauber, Joachim; Saini, Kulvinder Singh; Brandenburg, Klaus; Heinbockel, Lena; Krepstakies, Marcel; Hornef, Mathias; Özen, Mehmet Özgün; Khardori, N.M.; Garidel, Patrick; Nartop, Pınar; Schuch, Raymond; Sankar, S; Vennison, S. John; Dömming, Sabine; Wang, Shengqi; Schmeiser, Stefanie; Gülce-İz, Sultan; Sánchez-Gómez, Susana; Gutsmann, Thomas; Schürholz, Tobias; Protzer, Ulrike; Kelly, U.M.; Raj, V. Samuel; Fischetti, Vincent A.; Moennig, V.; Brune, Wolfram; Bo, Xiaochen; Luo, Xiaoxing; Kaconis, Yani; Sarwar, Yasra; You, Yu

doi:10.2174/97816810815331160201

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibiotics are the mainstay of therapy for infections, but have limitations, such as low penetrance on bacterial biofilms and side effects, including disruption of the microbiota and antimicrobial resistance (8). In addition, antibiotics have no effects on fungal and viral infections.…”

Section: Introductionmentioning

confidence: 99%

Sublingual Bacterial Vaccination Reduces Recurrent Infections in Patients With Autoimmune Diseases Under Immunosuppressant Treatment

et al. 2021

View full text Add to dashboard Cite

IntroductionConventional or biologic disease-modifying anti-rheumatic drugs (DMARDs) are the mainstay of treatment for systemic autoimmune disease (SAD). Infectious complications are a major concern in their use.ObjectiveTo evaluate the clinical benefit of sublingual mucosal polybacterial vaccines (MV130 and MV140), used to prevent recurrent respiratory and urinary tract infections, in patients with SAD and secondary recurrent infections following conventional or biologic DMARDs.MethodsAn observational study in SAD patients with recurrent respiratory tract infections (RRTI) and/or recurrent urinary tract infections (RUTI) was carried out. All patients underwent mucosal (sublingual) vaccination with MV130 for RRTI or with MV140 for RUTI daily for 3 months. Clinical evaluation was assessed during 12 months of follow-up after the first dose, i.e., 3 months under treatment and 9 months once discontinued, and compared with the previous year.ResultsForty-one out of 55 patients completed 1-year follow-up. All patients were on either conventional or biologic DMARDs. A significant decrease in the frequency of RUTI (p<0.001), lower respiratory tract infections (LRTI) (p=0.009) and upper respiratory tract infections (URTI) (p=0.006) at 12-mo with respect to the previous year was observed. Antibiotic prescriptions and unscheduled medical visits decreased significantly (p<0.020) in all groups. Hospitalization rate also declined in patients with RRTI (p=0.019). The clinical benefit demonstrated was concomitant to a significant increase in both anti-S. pneumoniae IgA and IgG antibodies following MV130 vaccination.ConclusionsSublingual polybacterial vaccines prevent recurrent infections in patients with SAD under treatment with immunosuppressant therapies, supporting a broad non-specific anti-infectious effect in these patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Sublingual Bacterial Vaccination Reduces Recurrent Infections in Patients With Autoimmune Diseases Under Immunosuppressant Treatment

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Here we provide a comprehensive clinical and immunological overview of a real-life cohort of SID-B-CLPD patients to build on infectious risk stratification, but also on second primary neoplasia, autoimmunity, and gastrointestinal involvement. Management of SID patients include IgRT and prophylactic antibiotics [ 23 , 24 , 25 ]. Trained immunity-based vaccines (TIbV) might be a promising adjuvant strategy to reduce infections in SID patients [ 26 , 27 , 28 ].…”

Section: Introductionmentioning

confidence: 99%

Combined Immune Defect in B-Cell Lymphoproliferative Disorders Is Associated with Severe Infection and Cancer Progression

et al. 2022

View full text Add to dashboard Cite

B cell chronic lymphoproliferative diseases (B-CLPD) are associated with secondary antibody deficiency and other innate and adaptive immune defects, whose impact on infectious risk has not been systematically addressed. We performed an immunological analysis of a cohort of 83 B-CLPD patients with recurrent and/or severe infections to ascertain the clinical relevance of the immune deficiency expression. B-cell defects were present in all patients. Patients with combined immune defect had a 3.69-fold higher risk for severe infection (p = 0.001) than those with predominantly antibody defect. Interestingly, by Kaplan–Meier analysis, combined immune defect showed an earlier progression of cancer with a hazard ratio of 3.21, than predominantly antibody defect (p = 0.005). When B-CLPD were classified in low-degree, high-degree, and plasma cell dyscrasias, risk of severe disease and cancer progression significantly diverged in combined immune defect, compared with predominantly antibody defect (p = 0.001). Remarkably, an underlying primary immunodeficiency (PID) was suspected in 12 patients (14%), due to prior history of infections, autoimmune and granulomatous conditions, atypical or variegated course and compatible biological data. This first proposed SID classification might have relevant clinical implications, in terms of predicting severe infections and cancer progression, and might be applied to different B-CLPD entities.

show abstract

Engineering of Vaginal Lactobacilli to Express Fluorescent Proteins Enables the Analysis of Their Mixture in Nanofibers

Stojanov

Plavec

Kristl

et al. 2021

IJMS

View full text Add to dashboard Cite

Lactobacilli are a promising natural tool against vaginal dysbiosis and infections. However, new local delivery systems and additional knowledge about their distribution and mechanism of action would contribute to the development of effective medicine. This will be facilitated by the introduction of the techniques for effective, inexpensive, and real-time tracking of these probiotics following their release. Here, we engineered three model vaginal lactobacilli (Lactobacillus crispatus ATCC 33820, Lactobacillus gasseri ATCC 33323, and Lactobacillus jensenii ATCC 25258) and a control Lactobacillus plantarum ATCC 8014 to express fluorescent proteins with different spectral properties, including infrared fluorescent protein (IRFP), green fluorescent protein (GFP), red fluorescent protein (mCherry), and blue fluorescent protein (mTagBFP2). The expression of these fluorescent proteins differed between the Lactobacillus species and enabled quantification and discrimination between lactobacilli, with the longer wavelength fluorescent proteins showing superior resolving power. Each Lactobacillus strain was labeled with an individual fluorescent protein and incorporated into poly (ethylene oxide) nanofibers using electrospinning, as confirmed by fluorescence and scanning electron microscopy. The lactobacilli retained their fluorescence in nanofibers, as well as after nanofiber dissolution. To summarize, vaginal lactobacilli were incorporated into electrospun nanofibers to provide a potential solid vaginal delivery system, and the fluorescent proteins were introduced to distinguish between them and allow their tracking in the future probiotic-delivery studies.

show abstract

Frontiers in Clinical Drug Research: Anti-Infectives

Cited by 3 publications

References 0 publications

Sublingual Bacterial Vaccination Reduces Recurrent Infections in Patients With Autoimmune Diseases Under Immunosuppressant Treatment

Sublingual Bacterial Vaccination Reduces Recurrent Infections in Patients With Autoimmune Diseases Under Immunosuppressant Treatment

Combined Immune Defect in B-Cell Lymphoproliferative Disorders Is Associated with Severe Infection and Cancer Progression

Engineering of Vaginal Lactobacilli to Express Fluorescent Proteins Enables the Analysis of Their Mixture in Nanofibers

Contact Info

Product

Resources

About